Cited by 1,132Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Risk of Alzheimer's disease and duration of NSAID use

Open access

Stewart, Walter F., Kawas, Claudia, Corrada, Maria, Metter, E. Jeffrey·1997·Neurology

DOI 10.1212/wnl.48.3.626

Open this paper in CoChat — free account Open PDF

Abstract

In a longitudinal study of 1,686 participants in the Baltimore Longitudinal Study of Aging, we examined whether the risk of Alzheimer's disease (AD) was reduced among reported users of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, we examined use of acetaminophen, a pain-relief medication with little or no anti-inflammatory activity, to assess the specificity of the association between AD risk and self-reported medications. Information on use of medications was collected during each biennial examination between 1980 and 1995. The relative risk (RR) for AD decreased with increasing duration of NSAID use. Among those with 2 or more years of reported NSAID use, the RR was 0.40 (95% confidence interval [CI]: 0.19-0.84) compared with 0.65 (95% CI: 0.33-1.29) for those with less than 2 years of NSAID use. The overall RR for AD among aspirin users was 0.74 (95% CI: 0.46-1.18), and no trend of decreasing risk of AD was observed with increasing duration of aspirin use. No association was found between AD risk and use of acetaminophen (RR = 1.35; 95% CI: 0.79-2.30), and there was no trend of decreasing risk with increasing duration of use. These findings are consistent with evidence from cross-sectional studies indicating protection against AD risk among NSAID users and with evidence suggesting that one stage of the pathophysiology leading to AD is characterized by an inflammatory process.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/wnl.48.3.626

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Boston Naming Test
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Bayes Estimates for the Linear Model
Lindley, D. V., & Smith, A. F. M. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00885.x · Cited by 2,025
Normal Human Aging: The Baltimore Longitudinal Study on Aging
Shock, N. W., Greulich, R. C., Costa, P. T., Andres, R., Lakatta, E. G., Arenberg, D., & Tobin, J. D. (1984) · University Libraries (University of Maryland) · doi:10.13016/sclw-iccq · Cited by 757
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Activation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383
Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes.
Stremmel, W., Strohmeyer, G. W., Borchard, F., Kochwa, S., & Berk, P. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.4 · Cited by 350
A Population-Based Study of the Risk of Recurrence of Birth Defects
Lie, R. T., Wilcox, A. J., & Skjærven, R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407073310101 · Cited by 164
Social adjustment and psychopathology among formerly hospitalized and non-hospitalized mothers—I. Development of the social role adjustment instrument
Cohler, B. J., ROBBINS, D. M., Hartman, C. R., Shader, R. I., Grunebaum, H. U., Gallant, D. H., & Weiss, J. L. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90017-5 · Cited by 132
The need for multiple time points in aging studies
Coleman, P. A., Finch, C. E., & Joseph, J. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90055-5 · Cited by 66

Flagged first, then by citations

Show all 16 references

Research works printed but not linked: 16

Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495.
Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982;57:239-252.
Anonymous. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
Morris JC, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-244.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
Checkoway H Pearce NE Crawford-Brown DJ. Research methods in occupational epidemiology monographs in epidemiology and biostatistics vol 13. New York: Oxford University Press 1989:153-155.
Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
Paulas HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN Harris ED Ruddy S Sledge CB eds. A textbook of rheumatology. Philadelphia: WB Saunders 1989.

Sorted by citations

Items 401–500 of 1,000

Complement activation as a biomarker for Alzheimer's disease
Aiyaz, M., Lupton, M. K., Proitsi, P., Powell, J. F., & Lovestone, S. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.023 · Cited by 69
Microglial interaction with β‐amyloid: Implications for the pathogenesis of Alzheimer's disease
Bamberger, M. E., & Landreth, G. E. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1121 · Cited by 74
Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases
Kadiu, I., Glanzer, J. G., Kipnis, J., Gendelman, H. E., & THOMAS, M. P. (2005) · Neurotoxicity Research · doi:10.1007/bf03033818 · Cited by 69
Function of human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase in androgen metabolism
He, X., Merz, G., Yang, Y., Pullakart, R., Mehta, P. D., Schulz, H., & Yang, S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00014-7 · Cited by 69
The prevalence of the neuropathological lesions of Alzheimer’s disease is independent of race and gender
Sandberg, G., Stewart, W., Smialek, J., & Troncoso, J. C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00236-0 · Cited by 68
Self-citation
Characterization of Scavengers of γ-Ketoaldehydes That Do Not Inhibit Prostaglandin Biosynthesis
Zagol-Ikapitte, I. A., Amarnath, V., Bala, M., Roberts, L. J., Oates, J. A., & Boutaud, O. G. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900407a · Cited by 68
Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 beta injections into the dorsal hippocampus
Hein, A. M., Stutzman, D. L., Bland, S. T., Barrientos, R. M., Watkins, L. R., Rudy, J. W., & Maier, S. F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.10.003 · Cited by 68
Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections)
Ringheim, G. E., & Conant, K. E. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.10.013 · Cited by 67
Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells
Klegeris, A., & McGeer, P. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 73
Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer???s Disease
Launer, L. J. (2003) · Drugs · doi:10.2165/00003495-200363080-00001 · Cited by 69
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development
Cutler, N. R., & Sramek, J. J. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00147-0 · Cited by 68
Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease
Huerta, C., Álvarez, V., Mata, I. F., Coto, E., Ribacoba, R., Martínez, C., Estrada, M. B., Guisasola, L. M., Salvador, C., Lahoz, C. H., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.08.016 · Cited by 67
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 68
Interleukin-13 Enhances Cyclooxygenase-2 Expression in Activated Rat Brain Microglia: Implications for Death of Activated Microglia
Yang, M.-S., Ji, K., Jeon, S., Jin, B.-K., Kim, S. U., Jou, I., & Joe, E.-H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1323 · Cited by 68
Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R., dell’Omo, R., & Semeraro, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/476525 · Cited by 69
Hepcidin attenuates amyloid beta‐induced inflammatory and pro‐oxidant responses in astrocytes and microglia
Urrutia, P. J., Hirsch, É. C., González-Billault, C. E., & Núñez, M. T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14005 · Cited by 68
Preventive Effects of Dairy Products on Dementia and the Underlying Mechanisms
Ano, Y., & Nakayama, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071927 · Cited by 66
Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease
Ellis, R. J., Jan, K., Kawas, C. H., Koller, W. C., Lyons, K. E., Jeste, D. V., Hansen, L. A., & Thal, L. J. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.360 · Cited by 66
Self-citation
Hydrogen sulfide inhibits ATP-induced neuroinflammation and Aβ1–42 synthesis by suppressing the activation of STAT3 and cathepsin S
Cao, L., Cao, X., Zhou, Y., Nagpure, B. V., Wu, Z., Hu, L. F., Yang, Y., Sethi, G., Moore, P. K., & Bian, J. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.07.005 · Cited by 64
Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway
Paris, D., Town, T., Mori, T., Parker, T. A., Humphrey, J., & MULLAN, M. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00111-6 · Cited by 66
Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population
Cornelius, C., Fastbom, J., Winblad, B. G., & Viitanen, M. H. (2004) · Neuroepidemiology · doi:10.1159/000075957 · Cited by 66
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE 2 Signaling in Alzheimer’s Disease
Woodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 62
Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?
Breitner, J., & Zandi, P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111223452110 · Cited by 72
Tryptophan-related dipeptides in fermented dairy products suppress microglial activation and prevent cognitive decline
Ano, Y., Yoshino, Y., Kutsukake, T., Ohya, R., Fukuda, T., Uchida, K., Takashima, A., & Nakayama, H. (2019) · Aging · doi:10.18632/aging.101909 · Cited by 64
Combining Ethnopharmacology and Virtual Screening for Lead Structure Discovery: COX-Inhibitors as Application Example
Rollinger, J. M., Haupt, S., Stuppner, H., & Langer, T. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci030031o · Cited by 63
N-Acetylcysteine and Celecoxib Lessen Cadmium Cytotoxicity Which Is Associated with Cyclooxygenase-2 Up-regulation in Mouse Neuronal Cells
Figueiredo‐Pereira, M. E., Li, Z., Jansen, M., & Rockwell, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109145200 · Cited by 62
Prostaglandin H2‐derived adducts of proteins correlate with Alzheimer's disease severity
Zagol-Ikapitte, I. A., Masterson, T. S., Amarnath, V., Montine, T. J., Andreasson, K. I., Boutaud, O. G., & Oates, J. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03264.x · Cited by 62
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice
Węgiel, J., Imaki, H., Wang, K.-C., Wegiel, J., & Rubenstein, R. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.058 · Cited by 62
Inflammation in the nervous system — Physiological and pathophysiological aspects
Schultzberg, M., Lindberg, C., Aronsson, Å. F., Hjorth, E., Spulber, S. D., & Oprica, M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.050 · Cited by 62
An Overview of the Etiology, Diagnosis, and Treatment of Alzheimer Disease
Forsyth, E., & Ritzline, P. D. (1998) · Physical Therapy · doi:10.1093/ptj/78.12.1325 · Cited by 62
Catalytic Antioxidants and Neurodegeneration
Golden, T. R., & Patel, M. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2256 · Cited by 62
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Félician, O., & Sandson, T. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.19 · Cited by 61
Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase‐2 inhibitor APHS can be reversed by a prostanoid
Carlson, N. G. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10465 · Cited by 61
Protection of rat primary hippocampal cultures from Aβ cytotoxicity by pro-inflammatory molecules is mediated by astrocytes
Ramírez, G., Toro, R., Döbeli, H., & von Bernhardi, R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.007 · Cited by 60
The impact of neuroimmune changes on development of amyloid pathology; relevance to A lzheimer's disease
Lynch, M. A. (2013) · Immunology · doi:10.1111/imm.12156 · Cited by 64
Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 59
Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration
Brenhouse, H. C., Chen, E., Emerich, D. F., Baldwin, S., Hogeland, K., Ranelli, S., Lafreniere, D., Perdomo, B., Novak, L., Kladis, T., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049700 · Cited by 60
Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease
Beher, D., & Graham, S. L. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1385 · Cited by 61
CD40–CD40L interaction in Alzheimer's disease
Tan, J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00180-7 · Cited by 57
Naringenin ameliorates amyloid-β pathology and neuroinflammation in Alzheimer’s disease
Zhu, Y., Guo, X., Li, S., Wu, Y., Zhu, F., Qin, C., Zhang, Q., & Yang, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06615-6 · Cited by 64
Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.
Kumari, B., Kumar, A., & Dhir, A. (2007) · PubMed · Cited by 58
DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case–control study
Chou, M.-H., Wang, J., Lin, C., & Chung, W. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.014 · Cited by 58
Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?
Mason, A., Holmes, C., & Edwards, C. J. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.001 · Cited by 59
CCR1 is an early and specific marker of Alzheimer's disease
Halks‐Miller, M., Schroeder, M. L., Haroutunian, V. H., Moenning, U., Rossi, M. R., Achim, C. L., Purohit, D. P., Mahmoudi, M., & Horuk, R. (2003) · Annals of Neurology · doi:10.1002/ana.10733 · Cited by 58
Autotransplantation of Bone Marrow-Derived Stem Cells as a Therapy for Neurodegenerative Diseases
Kan, I., Melamed, E., & Offen, D. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68976-8_10 · Cited by 60
COX-2 and Alzheimer’s disease: potential roles in inflammation and neurodegeneration
O’Banion, M. K. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1521 · Cited by 59
Pharmacogenomics of neurodegenerative diseases
Maimone, D., Dominici, R., & Grimaldi, L. M. E. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00939-0 · Cited by 56
Alzheimer Disease and Its Management
Samanta, M. K., Wilson, B., Santhi, K., Kumar, K. P. S., & Suresh, B. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000208274.80496.f1 · Cited by 54
Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions
Lodeiro, M., Puerta, E., Ismail, M.-A.-M., Rodriguez‐Rodriguez, P., Rönnbäck, A., Codita, A., Parrado‐Fernández, C., Maioli, S., Gil-Bea, F. J., Merino‐Serrais, P., et al. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw073 · Cited by 55
Mind the gaps: What we don't know about cognitive impairment in essential tremor
Louis, E. D., Joyce, J. L., & Cosentino, S. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.038 · Cited by 58
Cyclopentenone Eicosanoids as Mediators of Neurodegeneration: A Pathogenic Mechanism of Oxidative Stress-Mediated and Cyclooxygenase-Mediated Neurotoxicity
Musiek, E. S., Milne, G. L., McLaughlin, B., & Morrow, J. D. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00512.x · Cited by 57
What are all the things that aspirin does?
Flower, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7415.572 · Cited by 57
Pharmacologic treatment of cognition in Alzheimer's dementia
Farlow, M. R., & Evans, R. M. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s36 · Cited by 56
Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence
Veld, B. A. I. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/mxf001 · Cited by 56
Computer-Aided Design of Selective COX-2 Inhibitors: Comparative Molecular Field Analysis, Comparative Molecular Similarity Indices Analysis, and Docking Studies of Some 1,2-Diarylimidazole Derivatives
Desiraju, G. R., Gopalakrishnan, B., Jetti, R. K. R., Nagaraju, A., Raveendra, D., Sarma, J. A. R. P., Sobhia, M. E., & Thilagavathi, R. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020198t · Cited by 56
Identifying Dementia in the Primary Care Practice
Solomon, P. R., Calvo, V., Adams, F., DeVeaux, R. D., Pendlebury, W. W., & Sullivan, D. M. (2000) · International Psychogeriatrics · doi:10.1017/s1041610200006608 · Cited by 56
Indomethacin for Alzheimer's disease
Tabet, N., & Feldman, H. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003673 · Cited by 50
The role of polyunsaturated fatty acids (PUFAs) in development, aging and substance abuse disorders: Review and propositions
Borsonelo, E. C., & Galduróz, J. C. F. (2008) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.03.005 · Cited by 56
Medication appropriateness tool for co‐morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel
Page, A. T., Potter, K., Clifford, R. M., McLachlan, A. J., & Etherton‐Beer, C. (2016) · Internal Medicine Journal · doi:10.1111/imj.13215 · Cited by 60
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid
Lee, Y. T., & Wang, Q. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00485-9 · Cited by 56
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M. G., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 55
Cyclooxygenase‐2 inhibitors: promise or peril?
Mengle-Gaw, L. J., & Schwartz, B. D. (2002) · Mediators of Inflammation · doi:10.1080/09629350290000041 · Cited by 52
Minocycline reduces engraftment and activation of bone marrow‐derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease
Malm, T., Magga, J. M., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koıstınaho, J. (2008) · Glia · doi:10.1002/glia.20726 · Cited by 56
Prescribing for Australians living with dementia: study protocol using the Delphi technique
Page, A. T., Potter, K., Clifford, R. M., McLachlan, A. J., & Etherton‐Beer, C. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008048 · Cited by 55
RETRACTED: Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice
Zhang, W., Bai, M., Ye, X., Hao, J., Zhang, Z., Su, C., Lei, G., Miao, J., & Li, Z. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.023 · Cited by 53
Retracted
Cytokine signaling convergence regulates the microglial state transition in Alzheimer’s disease
Lau, S., Fu, A. K. Y., & Ip, N. Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03810-0 · Cited by 55
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 53
SELECTIVE CYCLOOXYGENASE-2 INHIBITORS
Golden, B. D., & Abramson, S. B. (1999) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70073-9 · Cited by 52
Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Halliday, G. M., Shepherd, C. E., McCann, H., Reid, W. G. J., Grayson, D. A., Broe, G. A., & Kril, J. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.831 · Cited by 72
Targeting the Endocannabinoid System in Alzheimer's Disease
Koppel, J. L., & Davies, P. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15315 · Cited by 51
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application
Pietrzik, C. U., & Behl, C. (2005) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2005.00435.x · Cited by 52
Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients
Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., & Bernabei, R. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00008 · Cited by 51
Sparing of age-related macular degeneration in rheumatoid arthritis
McGeer, P. L., & Sibley, J. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.003 · Cited by 51
Ibuprofen for Alzheimer's disease
Tabet, N., & Feldman, H. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004031 · Cited by 51
Therapeutic potential of dietary phase 2 enzyme inducers in ameliorating diseases that have an underlying inflammatory component
Juurlink, B. H. J. (2001) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y00-120 · Cited by 51
Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture
Rommy von Bernhardi, M., Ramírez, G., Toro, R., & Eugenín, J. L. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.006 · Cited by 51
Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice.
Cąkała, M., Malik, A. R., & Strosznajder, J. B. (2007) · PubMed · Cited by 50
Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study
Jonker, C., Comijs, H. C., & Smit, J. H. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00188-4 · Cited by 48
Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system
Klegeris, A., Bissonnette, C. J., & McGeer, P. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.012 · Cited by 54
15-Deoxy-Δ12,14-Prostaglandin J2 Protects against Nitrosative PC12 Cell Death through Up-regulation of Intracellular Glutathione Synthesis
Lim, S.-Y., Jang, J.-H., Na, H., Lu, S. C.-L., Rahman, I., & Surh, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406555200 · Cited by 50
Increased expression of the urokinase plasminogen-activator receptor in amyloid β peptide-treated human brain microglia and in AD brains
Walker, D. G., Lue, L., & Beach, T. G. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03298-x · Cited by 49
Learning deficits and dysfunctional synaptic plasticity induced by aggregated amyloid deposits in the dentate gyrus are rescued by chronic treatment with indomethacin
Stéphan, A., Laroche, S., & Davis, S. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02610.x · Cited by 53
Anti-inflammatory drugs: a hope for Alzheimer’s disease?
Hüll, M., Lieb, K., & Fiebich, B. L. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.671 · Cited by 49
The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models
Ma, Q., Zhu, C., Morselli, M., Su, T., Pelligrini, M., Lu, Z., Jones, M. R., Denver, P., Castro, D., Gu, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558036 · Cited by 48
Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer’s Disease
Tyagi, A., Kamal, M. A., & Poddar, N. K. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00693 · Cited by 50
Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARγ) in murine primary astrocytes and neurons
Klotz, L., Sastre, M., Kreutz, A., Gavrilyuk, V., Klockgether, T., Feinstein, D. L., & Heneka, M. T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01909.x · Cited by 48
Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants
Veurink, G. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00042-x · Cited by 49
Estrogen (E2) and glucocorticoid (Gc) effects on microglia and Aβ clearance in vitro and in vivo
Harris‐White, M. E., Chu, T., Miller, S., Simmons, M., Teter, B., Nash, D., Cole, G. M., & Frautschy, S. A. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00051-1 · Cited by 48
Estrogen: A Neuroprotective or Proinflammatory Hormone? Emerging Evidence from Reproductive Aging Models
Sohrabji, F. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1347.006 · Cited by 48
Alzheimer Disease Therapeutics
Irizarry, M. C., & Hyman, B. T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.923 · Cited by 49
Obovatol improves cognitive functions in animal models for Alzheimer’s disease
Choi, D., Lee, J. W., Peng, J., Lee, Y. J., Han, J., Lee, Y. H., Choi, I. S., Han, S., Jung, J., Lee, W. S., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07642.x · Cited by 46
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., & Wirths, O. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.006 · Cited by 46
Colostrinin™: An Oxidative Stress Modulator for Prevention and Treatment of Age-related Disorders
Boldogh, I. R., & Kruzel, M. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13308 · Cited by 45
TREATMENT OF ALZHEIMER'S DISEASE
Grundman, M., & Thal, L. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70227-9 · Cited by 46
Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia
Chen, S., Averett, N. T., Manelli, A. M., LaDu, M. J., May, W., & Ard, M. D. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7104 · Cited by 46
Nimesulide — Actions and Uses
Rainsford, K. D. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7410-1 · Cited by 46
Effects of S‐2474, a novel nonsteroidal anti‐inflammatory drug, on amyloid β protein‐induced neuronal cell death
Yagami, T., Ueda, K., Asakura, K., Sakaeda, T., Kuroda, T., Hata, S., Kambayashi, Y., & Fujimoto, M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704261 · Cited by 46

Authors: Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J.
Affiliations: Johns Hopkins University (US)
ORCID: Stewart, Walter F.
Kawas, Claudia
Metter, E. Jeffrey
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-03
Volume: 48
Issue: 3
Pages: 626-632
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.48.3.626
OpenAlex: W2163110760
Cited by: 1,132
References: 16
Citations by year: 2026: 5 · 2025: 9 · 2024: 13 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 21 · 2017: 24 · 2016: 28 · 2015: 29 · 2014: 32 · 2013: 24 · 2012: 31
FWCI: 42.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: American Academy of Neurology
National Institutes of Health
National Institute on Aging (R01AG008325, R01-AG08325)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: Alzheimer's disease, nonsteroidal anti-inflammatory drugs, aspirin, paracetamol, medication use, neuroprotection, neuroinflammation
MeSH terms: Acetaminophen, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Confidence Intervals, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of Alzheimer's disease and duration of NSAID use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks